ESCRS - New Trifocal IOL Delivers Positive Outcomes
Cataract, Refractive, IOL, Refractive Surgery

New Trifocal IOL Delivers Positive Outcomes

Seven diffractive rings offer full range of vision.

New Trifocal IOL Delivers Positive Outcomes
Dermot McGrath
Dermot McGrath
Published: Monday, July 1, 2024

Initial clinical results of a new trifocal IOL (Triva-aXAY, HumanOptics) with a novel diffractive design and a large optic have demonstrated excellent performance in terms of visual acuity and delivering high levels of patient satisfaction, according to Pavel Stodůlka MD, PhD.

“This lens has an innovative and very smooth implantation technique and delivers excellent monocular and binocular visual acuities at all distances,” he said. “Notably, over one-third of patients reported no dysphotopsia at all, while low numbers of patients reported strong halo and glare effects, which is an impressive performance for a trifocal lens.”

Dr Stodůlka said matching the appropriate IOL to the right patient profile is the key to success.

“It is now more than 75 years since the first IOL was implanted, and it is good to see the pace of innovation continues today,” he said. “The properties of this trifocal lens may offer the anticipated level of vision quality sought by individuals with high expectations and a desire for freedom from spectacles.”

Discussing the properties of the Triva-aXAY, Dr Stodůlka explained it is a hydrophilic acrylic lens with a 7.0 mm large optic, seven diffractive rings, near additions of +1.75 D and +3.50 D, and a 3.5 mm diffractive zone. The lens offers built-in powers ranging from +10.00 to +30.00 D in 0.50 D increments.

“The optic is designed to minimize dysphotopsia, even in larger pupils, and, with only 7 diffractive rings, achieves similar or even better results than traditional trifocal with up to 26 diffractive rings,” he said. “Because the IOL was bigger than other designs, we had some difficulties with implantation with the first models—but our new proprietary implantation technology has resolved this issue and made it very easy and smooth to deliver the lens into the capsular bag.”

One of the novelties of this lens is the plate cut-out haptics are folded underneath the optic at the moment of delivery into the capsular bag.

“We enter with the cartridge inside the eye at the level of the capsulorhexis, and when the optic leaves the cartridge tip, the whole lens unfolds easily in the capsular bag. It is super easy,” Dr Stodůlka explained. “Then we aspirate the viscoelastic and clean up the eye, and we end up with a well-centred large optic with a much lower risk of dysphotopsia coming from the edge.”

Dr Stodůlka’s study included 32 eyes of 16 patients with a median age of 58 years implanted with Triva-aXAY as part of routine cataract surgery. Median IOL power was 23.50 D, and follow-up was set at six months.

“In terms of results, we got what we expected, and the patients were happy,” he noted. “All eyes had corrected distance visual acuity (CDVA) of 0.1 logMAR or better, and 0.2 logMAR or better was achieved in 78% of eyes for distance corrected intermediate vision acuity (DCIVA) at 80 cm and 97% of eyes for distance corrected near visual acuity (DCNVA) at 40 cm.”

The binocular corrected visual acuity outcomes were also satisfactory, with all patients achieving 0.3 logMAR or better at all distances. The spherical equivalent refractive accuracy showed a slightly myopic outcome with 53% of eyes from -0.14 D to -1.00 D and 75% of eyes within ±0.50 D of target refraction.

“That is a very nice outcome for an initial series,” Dr Stodůlka said.

Regarding dysphotopsia, halo was reported as ‘no or mild’ in 79%, glare as ‘no or mild’ in 64%, starburst in 64%, and 36% of patients reported no photic phenomena at all.

“For a diffractive full range of vision IOL, these are very nice results indeed,” he concluded.

Dr Stodůlka presented at the 2024 ESCRS Winter Meeting in Frankfurt.

Pavel Stodůlka MD, PhD, FEBOS-CR is founder, chief surgeon, and CEO of Gemini Eye Clinics in the Czech Republic and Vienna, Austria. stodulka@lasik.cz

Tags: dysphotopsia, trifocal IOL, Stodulka, Pavel
Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...